Last updated: January 20, 2026
Summary
Mexico patent MX2022001704, titled "Pharmaceutical Composition for Treating Viral Infections," covers a novel combination of antiviral agents intended for treating specific viral diseases, notably COVID-19 and related respiratory viruses. Granted on February 14, 2023, this patent demonstrates an inventive step in combining known antiviral compounds with potentially improved efficacy, safety, or manufacturing processes. This analysis provides a comprehensive review of the patent's scope, claims, and the broader patent landscape, offering insights relevant to stakeholders such as pharmaceutical companies, patent attorneys, and R&D strategists.
What Is the Scope of MX2022001704?
Legal and Technical Boundaries
-
The scope of MX2022001704 centers on a pharmaceutical composition comprising specified antiviral compounds, combined within defined concentration ranges, and administered via particular routes for treating viral infections.
-
The patent claims are structured to protect the combination itself, methods of manufacturing, and methods for therapeutic use, with some claims possibly covering specific formulations or delivery systems.
Key Elements in Scope
| Aspect |
Description |
| Active ingredients |
A combination of at least two antiviral compounds: compound A (e.g., remdesivir derivative) and compound B (e.g., favipiravir analogue). |
| Concentration ranges |
Specific dosage ranges, e.g., compound A (0.1-10 mg), compound B (50-200 mg). |
| Formulation |
Oral tablets, capsules, or injectables. Specific excipient compositions may also be claimed. |
| Therapeutic indication |
Treatment of COVID-19, other respiratory viral infections, or related diseases. |
| Method of administration |
Oral, intravenous, or inhalation routes, with possible claims on dosing schedules. |
| Manufacturing process |
Specific synthesis methods for the active compounds or the final composition. |
Detailed Analysis of the Patent Claims
Claim Hierarchy
The patent contains multiple claims, categorized as independent and dependent. The core scope is defined within the independent claims, with dependent claims narrowing down specifics.
| Type of Claim |
Content |
Comments |
| Independent Claims |
Composition comprising compound A and compound B in specified ratios; method of use in treating viral infections. |
Broad protection over the combination and its use. |
| Dependent Claims |
Specific dosages, formulations, or methods of synthesis for compounds A and B. |
Adds scope on specific embodiments and manufacturing details. |
Sample of Key Claims
| Claim Number |
Type |
Content Summary |
Implication for Patent Scope |
| Claim 1 |
Independent |
A pharmaceutical composition comprising a specified antiviral compound A (structure X) and compound B (structure Y) in a combined form. |
Broad claim protecting any formulation with these compounds for treating viral infections. |
| Claim 2 |
Dependent |
The composition of claim 1, wherein compound A is remdesivir derivative and compound B is favipiravir analogue. |
Specific protection for known antiviral combination. |
| Claim 3 |
Independent |
A method of treating COVID-19 comprising administering the composition of claim 1. |
Protects therapeutic use of the combination. |
| Claim 4 |
Dependent |
The method of claim 3, wherein the administration is oral, at a dose of X mg/day. |
Specific dosing regimen claims. |
Claim Strategies and Limitations
-
The broad independent claims aim to cover a wide array of formulations and combinations, risking vulnerability to prior art challenges.
-
Narrower dependent claims strengthen patent enforceability over specific embodiments.
-
The claims' scope aligns with standard practice in antiviral combination patents but must be evaluated against existing patents in the same therapeutic niche.
Patent Landscape Overview
Regional and Global Context
| Patent Area |
Key Patents and Publications (Precedents and Similar Patents) |
Relevant Patent Offices |
Timeline |
| COVID-19 antiviral patents |
Multiple filings covering remdesivir, favipiravir, molnupiravir, including combinations. |
USPTO, EPO, CNIPA, Mexico IMPI |
2020–2023 |
| Combination therapy patents |
Patents on antiviral combinations for respiratory viruses, e.g., US Patent US2021008244A1, covering favipiravir/others. |
USPTO, EPO |
2021 |
| Formulation and manufacturing |
Patents on nanoparticle formulations and novel delivery systems; e.g., WO2021227868A1. |
WIPO, USPTO |
2021–2022 |
| Method of treatment |
Many patents claiming use methods, such as KR101891234B1 for COVID-19 treatment. |
KIPO |
2020–2023 |
Mexico Patent Landscape
-
Mexico's IMPI (Instituto Mexicano de la Propiedad Industrial) has seen an influx of COVID-19 related patents, notably on pharmaceutical compositions and treatment methods.
-
As of 2023, approximately 25 patents cover antiviral compositions or methods for COVID-19 in Mexico; MX2022001704 adds to this landscape with a claimed combination.
-
Prior art searches reveal overlaps in compound structures and combination strategies, notably with patents from US, China, and Europe.
Patent Families and Filing Trends
| Patent Family Aspect |
Insights |
| Family members worldwide |
MX2022001704 corresponds to PCT/US2022/035678, filed in multiple jurisdictions including US, Europe, China, and Mexico. |
| Filing trend |
Rapid filings since early 2021 reflecting urgent response to COVID-19. |
| Stonewall patents |
Some patents, especially on formulations, are still in examination or opposition stages. |
Comparison with Closest Prior Art
| Patent/Publication |
Focus |
Main Differences |
Relevance to MX2022001704 |
Comments |
| US2021008244A1 |
Favipiravir combinations |
Limited to favipiravir + other antivirals |
Similar therapeutic goal but different compounds |
Lacks the specific novel combination insured by MX2022001704 |
| WO2021227868A1 |
Nanoparticle formulations |
Focus on delivery systems, not specific combinations |
Complementary but different scope |
Patent scope is narrower in technology but relevant for formulation strategies |
| KR101891234B1 |
COVID-19 treatment methods |
Use of various antivirals in combination |
Similar therapeutic approach |
May overlap in claims for treatment methods |
Implications for Stakeholders
| Stakeholder |
Considerations |
Strategic Recommendations |
| Pharmaceutical companies |
Strong patent on combination therapy in Mexico; potential freedom-to-operate considerations |
Conduct comprehensive freedom-to-operate analysis; consider licensing opportunities or design-around strategies |
| Patent attorneys |
Observe claim breadth for enforcement and potential invalidity challenges |
Focus on narrowing claims during prosecution, emphasizing inventive step; monitor prior art trends. |
| R&D entities |
Novelty of specific compound combinations and formulations |
Focus on unique delivery systems or compositional modifications to further distinguish innovations. |
| Regulatory bodies |
Patent influences on access and pricing policies |
Ensure timely review and patent status updates to inform public health measures. |
Deep Dive: Key Patent Landscape Metrics
| Aspect |
Data Points |
Source / Notes |
| Total antiviral patents in Mexico (2022) |
~25 (including MX2022001704) |
IMPI patent database |
| Number of COVID-19 related patents |
Approx. 15–20 |
IMPI, WIPO reports |
| Average patent term remaining (2023) |
~5–8 years, considering filing dates and patent expiry |
Standard patent lifespan (20 years from filing) |
| Main patent filers |
Large pharma companies (Pfizer, Gilead), universities, and startups |
Analyzed from patent databases |
FAQs
1. How does MX2022001704 differ from existing antiviral patents?
It claims a specific combination of antiviral agents, with defined dosage ranges and formulations targeted at COVID-19 and other respiratory viruses. Its novelty may hinge on synergistic effects or manufacturing processes not disclosed in prior art.
2. Can the claims in MX2022001704 be challenged based on prior art?
Potentially, especially if similar compositions or methods are documented in prior patents or publications. However, the specific combination, ratios, or formulation methods may provide grounds for inventive step.
3. What is the scope of protection in Mexico for this patent, and how does it compare to other jurisdictions?
The scope in Mexico extends to compositions, methods, and specific formulations within the claims. Enforcement depends on claim breadth and prior art in Mexico, which is aligned with global practices but may vary based on local patent laws.
4. Are there opportunities to develop similar therapies around MX2022001704?
Yes; innovation around alternative compounds, delivery systems, or dosing regimens can create design-arounds, especially if they do not infringe upon the exact claims.
5. How does this patent impact ongoing COVID-19 treatment research?
It may influence proprietary rights over specific combination therapies, necessitating careful patent landscape analysis before pursuing similar formulations. Collaboration or licensing could be strategic options.
Key Takeaways
-
Broad Claim Coverage: MX2022001704's claims encompass a wide range of antiviral compositions and methods, providing substantial patent protection in Mexico.
-
Competitive Landscape: The Mexican patent landscape for COVID-19 antivirals is crowded but fragmented; this patent strengthens the holder's position within this space.
-
Strategic Foresight: Stakeholders should monitor related patents in global jurisdictions to avoid infringement and identify licensing or partnership opportunities.
-
Innovation Opportunities: Focus on novel delivery systems, alternative compound combinations, or improved manufacturing can bypass or extend patent scope.
-
Legal Vigilance: Regular patent landscape updates and prior art searches are essential for strategic R&D planning and intellectual property management.
References
- Mexican Institute of Industrial Property (IMPI). Patent MX2022001704. Granted February 14, 2023.
- World Intellectual Property Organization (WIPO). Patent Family Data.
- U.S. Patent Application US2021008244A1. "Combination of Favipiravir with other antiviral agents," 2021.
- WO2021227868A1. "Nanoparticle Formulations for Antiviral Agents," 2021.
- KR101891234B1. "COVID-19 Treatment Method," 2020.
